[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2005000103A - Derivados de tetrahidroisoquinolinsulfonamidas. - Google Patents

Derivados de tetrahidroisoquinolinsulfonamidas.

Info

Publication number
DOP2005000103A
DOP2005000103A DO2005000103A DO2005000103A DOP2005000103A DO P2005000103 A DOP2005000103 A DO P2005000103A DO 2005000103 A DO2005000103 A DO 2005000103A DO 2005000103 A DO2005000103 A DO 2005000103A DO P2005000103 A DOP2005000103 A DO P2005000103A
Authority
DO
Dominican Republic
Prior art keywords
derivatives
present
tetrahydroisoquinolinsulphonamids
disorders
wakefulness
Prior art date
Application number
DO2005000103A
Other languages
English (en)
Inventor
Martin Juan Antonio Diaz
Bargueno Maria Dolores Jimenez
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34944870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2005000103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2005000103A publication Critical patent/DOP2005000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención tiene por objeto derivados de sulfonamidas, sus preparaciones y sus aplicaciones en terapéutica, en especial, en el tratamiento de los trastornos que presentan una mejoría por modulación del receptor H3 de la histamina, tales como la obesidad, la diabetes y las enfermedades del sistema nervioso central, tales como los trastornos de la vigilia y del sueño. En consecuencia la presente invención tiene como primer objeto los compuestos que responden a la fórmula I:
DO2005000103A 2004-05-25 2005-05-25 Derivados de tetrahidroisoquinolinsulfonamidas. DOP2005000103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405607A FR2870846B1 (fr) 2004-05-25 2004-05-25 Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
DOP2005000103A true DOP2005000103A (es) 2006-02-15

Family

ID=34944870

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2005000103A DOP2005000103A (es) 2004-05-25 2005-05-25 Derivados de tetrahidroisoquinolinsulfonamidas.

Country Status (41)

Country Link
US (3) US7833999B2 (es)
EP (1) EP1753725B1 (es)
JP (1) JP4861979B2 (es)
KR (1) KR101176675B1 (es)
CN (1) CN1956962B (es)
AR (1) AR050250A1 (es)
AU (1) AU2005250197B2 (es)
BR (1) BRPI0511581A (es)
CA (1) CA2565293C (es)
CR (1) CR8735A (es)
CY (1) CY1114240T1 (es)
DK (1) DK1753725T3 (es)
DO (1) DOP2005000103A (es)
EA (1) EA010234B1 (es)
EC (1) ECSP067020A (es)
ES (1) ES2407140T3 (es)
FR (1) FR2870846B1 (es)
GT (1) GT200500126A (es)
HK (1) HK1106229A1 (es)
HN (1) HN2005000239A (es)
HR (1) HRP20130431T1 (es)
IL (1) IL179021A (es)
JO (1) JO2877B1 (es)
MA (1) MA28720B1 (es)
MX (1) MXPA06013629A (es)
MY (1) MY148980A (es)
NI (1) NI200600279A (es)
NO (1) NO338104B1 (es)
NZ (1) NZ551509A (es)
PA (1) PA8634501A1 (es)
PE (1) PE20060273A1 (es)
PL (1) PL1753725T3 (es)
PT (1) PT1753725E (es)
SI (1) SI1753725T1 (es)
SV (1) SV2006002126A (es)
TN (1) TNSN06356A1 (es)
TW (1) TWI360540B (es)
UA (1) UA84771C2 (es)
UY (1) UY28917A1 (es)
WO (1) WO2005118547A1 (es)
ZA (1) ZA200609820B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
US7888354B2 (en) 2007-11-13 2011-02-15 Taisho Pharmaceutical Co., Ltd Phenylpyrazole derivatives
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
KR101804749B1 (ko) 2009-06-26 2017-12-05 사노피 히스타민 ｈ3 수용체 길항제의 신규 푸마레이트 염
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
CN103958499A (zh) 2011-12-08 2014-07-30 大正制药株式会社 苯基吡咯衍生物
EP2799436A4 (en) 2011-12-27 2015-07-01 Taisho Pharmaceutical Co Ltd PHENYLTRIAZOLDERIVAT
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
KR20160048930A (ko) * 2013-09-09 2016-05-04 사노피 알츠하이머 질환의 치료에 사용하기 위해 콜린에스테라제 저해제와 조합된 h3 수용체 길항제
CN110642854A (zh) * 2019-11-20 2020-01-03 成都克莱蒙医药科技有限公司 一种稠环化合物的多晶型、其组合物、制备方法及其应用
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702671A4 (en) 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
EP0882023B1 (en) * 1996-02-09 2003-06-04 James Black Foundation Limited Histamine h 3 receptor ligands
SG74717A1 (en) 1998-04-10 2000-08-22 Japan Tobacco Inc Amidine compound
WO2000071507A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
MXPA03005854A (es) 2001-01-02 2003-09-10 Hoffmann La Roche Derivados de quinazolona como antagonistas del receptor adrenergico alfa 1a/b.
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP2005513154A (ja) * 2001-12-26 2005-05-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿素誘導体
JP2003192660A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
US7220306B2 (en) 2002-03-08 2007-05-22 Sakata Ink Corp. Treated pigment, use thereof, and compound for treating pigment
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
WO2004019935A1 (en) * 2002-08-29 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
MXPA06004005A (es) 2003-10-08 2006-06-28 Vertex Pharma Moduladores de transportadores con casete de union con atp.
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
ES2257168B1 (es) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
US20080261999A1 (en) 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
EP1790646A1 (fr) 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.

Also Published As

Publication number Publication date
NO20065918L (no) 2006-12-19
EA200602176A1 (ru) 2007-04-27
JO2877B1 (en) 2015-03-15
DK1753725T3 (da) 2013-05-27
MXPA06013629A (es) 2007-03-23
EA010234B1 (ru) 2008-06-30
SI1753725T1 (sl) 2013-06-28
CR8735A (es) 2007-08-28
UA84771C2 (uk) 2008-11-25
HN2005000239A (es) 2009-04-27
CY1114240T1 (el) 2016-08-31
JP4861979B2 (ja) 2012-01-25
FR2870846B1 (fr) 2006-08-04
BRPI0511581A (pt) 2008-01-02
CA2565293C (fr) 2012-10-30
US8524700B2 (en) 2013-09-03
PE20060273A1 (es) 2006-04-22
UY28917A1 (es) 2005-12-30
TW200609220A (en) 2006-03-16
EP1753725B1 (fr) 2013-02-27
US20070105834A1 (en) 2007-05-10
CN1956962A (zh) 2007-05-02
KR20070021223A (ko) 2007-02-22
TNSN06356A1 (en) 2008-02-22
NI200600279A (es) 2008-01-22
US20120323003A1 (en) 2012-12-20
CA2565293A1 (fr) 2005-12-15
AU2005250197A1 (en) 2005-12-15
US8273733B2 (en) 2012-09-25
SV2006002126A (es) 2006-01-13
AU2005250197B2 (en) 2010-09-23
PL1753725T3 (pl) 2013-07-31
US7833999B2 (en) 2010-11-16
HRP20130431T1 (en) 2013-06-30
EP1753725A1 (fr) 2007-02-21
NO338104B1 (no) 2016-08-01
CN1956962B (zh) 2014-08-20
NZ551509A (en) 2009-12-24
PA8634501A1 (es) 2006-05-16
ES2407140T3 (es) 2013-06-11
KR101176675B1 (ko) 2012-08-23
IL179021A (en) 2012-04-30
WO2005118547A1 (fr) 2005-12-15
AR050250A1 (es) 2006-10-11
MA28720B1 (fr) 2007-07-02
GT200500126A (es) 2006-02-17
JP2008500313A (ja) 2008-01-10
US20110028475A1 (en) 2011-02-03
MY148980A (en) 2013-06-28
TWI360540B (en) 2012-03-21
PT1753725E (pt) 2013-05-21
FR2870846A1 (fr) 2005-12-02
IL179021A0 (en) 2007-03-08
HK1106229A1 (en) 2008-03-07
ECSP067020A (es) 2006-12-29
ZA200609820B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
DOP2005000103A (es) Derivados de tetrahidroisoquinolinsulfonamidas.
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
EA201300213A1 (ru) Применение ингибиторов dpp iv
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
CR20130580A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
CO6321264A2 (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CL2004000182A1 (es) Compuestos derivados de pirazolotriazina; y composicion farmaceutica util para tratar enfermedades y/o trastornos modulados por antagonistas de receptor de canabinoides, como la obesidad.
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
GT201100308A (es) Derivados de 1-(piperidin-4-il)-pirazol como moduladores de gpr 119
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201100623A1 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
CY1114952T1 (el) Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων
CO2021001292A2 (es) Compuestos inmunomoduladores diméricos contra mecanismos basados en cereblon
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
UY28945A1 (es) Derivados de pirrolopiridina
BR112015022307A2 (pt) derivados substituídos indol-5-ol e as suas aplicações terapêuticas